Ennature Bio Pharma Limited made its stock market debut on the National Stock Exchange and BSE on Wednesday, November 4, 2026. The company, a demerged division of India Glycols Limited.
The company reported net revenue of ₹246 crore, EBITDA of ₹29 crore, and a gross margin of 40.1 per cent for FY26. Its operations span three segments: active pharmaceutical ingredients (API), biopolymers, and nutraceuticals.
APIs form the largest business, contributing 67 per cent of sales. The portfolio includes thiocolchicoside, colchicine, nicotine, and vinpocetine, serving over 150 customers across 26 countries, with exports at 54 per cent of segment revenue.
The biopolymer segment, focused on guar gum and specialty gums, accounts for 16 per cent of sales with 69 per cent export contribution across 23 countries.
Nutraceuticals, currently at 17 per cent of sales, is the stated primary growth driver. The company’s five branded ingredients — Aspargize, Gingeren, Maxicuma, Xanthogreen, and Berbisol — serve over 90 customers in 19 countries, with exports at 83 per cent of segment revenue.
Manufacturing facilities in Dehradun and Kashipur hold capacities of 1,600 and 24,000 metric tonnes respectively, certified under EU-GMP, USFDA, and NSF-GMP standards. The company holds nine patents filed, five granted, and is running 20 clinical trials.
Published on November 4, 2026
